CRON:NSD-Cronos Group Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 7.29

Change

-0.40 (-5.20)%

Market Cap

USD 2.86B

Volume

3.75M

Average Target Price

USD 9.00 (+23.46%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Company Website : http://www.thecronosgroup.com

Address : 111 Peter Street, Toronto, ON, Canada, M5V 2H1

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.87

52 Week High : 15.83

Short Ratio : 7.79

52 Week Low : 4.62

Shorted Shares : 21,797,468

200 Day Moving Average : 8.95

Shorted Shares Previous Month : 21,592,601

50 Day Moving Average : 8.57

Shares Held By Insiders : 492.16%

Short Percentage : 6.00%

Shares Held by Institutions : 14.53%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

-1.08 (-4.28%)

 USD9.65B N/A N/A
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
TLRY Tilray, Inc

-1.14 (-7.05%)

 USD7.22B N/A N/A
APHA Tilray, Inc

-1.14 (-7.05%)

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
PCRX Pacira BioSciences, Inc

-2.36 (-3.73%)

 USD2.78B 19.02 40.01
ORGO Organogenesis Holdings Inc

-1.86 (-8.79%)

 USD2.71B 132.19 72.85
IRWD Ironwood Pharmaceuticals, Inc

+0.02 (+0.14%)

 USD1.78B 12.22 12.61
SUPN Supernus Pharmaceuticals, Inc

-0.02 (-0.07%)

 USD1.56B 14.22 8.94
ENDP Endo International plc

-0.35 (-6.22%)

 USD1.31B 13.87 8.22

ETFs Containing CRON

Symbol Name Weight Mer Price(Change) Market Cap
FDTS First Trust Developed Mar.. 0.00 % 0.80 %

+0.84 (+1.77%)

 USD9.42M
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.64 (-3.00%)

 USD1.71B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.75 %

-1.22 (-4.68%)

 N/A
THCX The Cannabis ETF 0.00 % 0.70 %

-0.85 (-4.80%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.04% 60% D- 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.04% 60% D- 50% F
Trailing 12 Months  
Capital Gain 38.33% 68% D+ 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.33% 68% D+ 44% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.16% 72% C- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.16% 72% C- 56% F
Risk Return Profile  
Volatility (Standard Deviation) 65.60% 30% F 26% F
Risk Adjusted Return 17.01% 67% D+ 37% F
Market Capitalization 2.86B 95% A 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.00 31% F 29% F
Price/Book Ratio 1.67 85% B 71% C-
Price / Cash Flow Ratio -20.09 83% B 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -4.32% 80% B- 47% F
Return on Invested Capital -10.44% 62% D- 33% F
Return on Assets -5.28% 65% D 33% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.79 33% F 12% F
Short Percent 11.41% 35% F 18% F
Beta 1.87 20% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector